EJNMMI Radiopharmacy and Chemistry, published by SpringerNature, stands at the forefront of research in the critical fields of radiopharmacy and nuclear medicine. With an impressive impact factor and a dedicated Open Access policy since 2016, this journal invites the global scientific community to share advancements in the synthesis, development, and application of radiopharmaceuticals within the realm of analytical chemistry and pharmacology. As evidenced by its notable categorizations, including Q1 in Analytical Chemistry and Radiology, Nuclear Medicine and Imaging, along with high Scopus rankings, EJNMMI offers a prestigious platform for rigorous peer-reviewed research that informs and inspires progress in medical imaging and therapeutics. The journal's commitment to accessibility fosters collaboration and innovation, making it an essential resource for researchers, medical professionals, and students seeking to advance their understanding and application of radiopharmaceuticals.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, published by Edizioni Minerva Medica in Italy, serves as a pivotal platform for researchers and practitioners in the fields of Nuclear Medicine and Molecular Imaging. With an ISSN of 1824-4785 and an E-ISSN of 1827-1936, this journal boasts a respectable impact factor and is positioned in the Q3 quartile of the Radiology, Nuclear Medicine and Imaging category, based on the latest 2023 evaluations. As the journal continues to converge from its inception in 2004 to its anticipated expansions through 2024, it aims to disseminate high-quality, peer-reviewed articles that advance the frontier of imaging technologies and their applications in clinical practice. Researchers, professionals, and students are encouraged to contribute to its diverse scope, which encompasses innovative research, clinical findings, and reviews that encapsulate cutting-edge advancements in the field, highlighting its importance as an essential resource for knowledge and collaboration.

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

Molecular Imaging and Radionuclide Therapy is an esteemed academic journal published by GALENOS PUBL HOUSE, dedicated to advancing the fields of radiology, nuclear medicine, and imaging. Since its inception, this Open Access journal has facilitated the dissemination of high-quality research and innovative practices in molecular imaging and radionuclide therapy, making it a vital resource for researchers, professionals, and students alike. With an ISSN of 2146-1414 and an E-ISSN of 2147-1959, the journal has established its presence globally while specifically catering to the Turkish academic and medical community. As of 2023, it is ranked #241/333 in the Radiology, Nuclear Medicine and Imaging category on Scopus, holding a respectable Q3 quartile ranking. The journal serves as a platform for sharing impactful findings from 2017 to 2024, reinforcing its commitment to open access since 2011. With a dedication to enhancing the knowledge base in molecular imaging and therapy, it remains an important conduit for scholarly communication and collaborative research developments in this dynamic field.

NUCLEAR MEDICINE REVIEW is a distinguished journal in the field of radiology, nuclear medicine, and imaging, published by VIA MEDICA in Poland. Since its transition to an open access format in 1999, this journal has been dedicated to promoting the dissemination of knowledge and research findings across a global audience. With a focus on innovative approaches and advancements in nuclear medicine, it aims to serve as a key resource for researchers, professionals, and students who are working to further the understanding of nuclear imaging and its applications. In 2023, the journal was classified in the Q3 category within Radiology, Nuclear Medicine and Imaging, and Q4 in the broader category of Medicine (miscellaneous), highlighting its growing reputation in the academic community. As of the latest assessments, the journal has been ranked #235 out of 333 in its field according to Scopus metrics, reflecting its commitment to excellence and the relevance of its published works. The NUCLEAR MEDICINE REVIEW is a pivotal platform for those engaged in cutting-edge research, providing insights that drive the evolution of medical imaging and therapeutic techniques.

ROFO-Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, published by Georg Thieme Verlag KG, is a pivotal journal in the fields of radiology and nuclear medicine, offering invaluable insights for researchers, healthcare professionals, and students alike. With an ISSN of 1438-9029, this journal has been a stalwart of scientific communication since its inception in 1975, actively contributing to advancements in imaging techniques and radiation therapy. Although it operates under traditional access, the journal maintains a respectable standing, reflected by its Q3 ranking in Radiology, Nuclear Medicine and Imaging and Q4 in Medicine (miscellaneous), highlighting its significance in the scholarly community. Its coverage spans a wide array of topics pertinent to diagnostic imaging and therapy protocols, making it an essential resource for anyone seeking to understand the complexities of modern radiological practices. As the journal continues to evolve through 2024, it invites contributions that enrich the dialogue around technological innovations and clinical applications in the realm of imaging modalities.

Revista Española de Medicina Nuclear e Imagen Molecular, published by Elsevier España SLU, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Molecular Imaging. With an ISSN of 2253-654X, this journal is committed to disseminating high-quality research and advancements in clinical practices, aiming to bridge the gap between theoretical research and application in healthcare. Operating since 2012, it features a robust archive of peer-reviewed articles and case studies, although it currently holds a Q4 ranking in the Scopus category, indicating significant potential for growth and influence within the academic community. The journal is indexed in Scopus, with a rank of 255 out of 333, placing it in the 23rd percentile, which underlines the need for increased contributions from researchers eager to enhance its standing. While it is not an open-access journal, its availability through libraries and institutions ensures that a wide audience can access critical findings and innovations in the rapidly evolving field of nuclear medicine. As we look towards the convergence period from 2012 to 2024, Revista Española de Medicina Nuclear e Imagen Molecular aspires to fortify its role as a cornerstone for collaboration and advancement in nuclear imaging and radiology.

Current Radiopharmaceuticals, published by Bentham Science Publishers Ltd, is an esteemed journal dedicated to advancing the field of radiopharmaceuticals. With an ISSN of 1874-4710 and an E-ISSN of 1874-4729, this journal has been a significant platform for researchers since its inception in 2009, and will continue to contribute to the literature until at least 2024. Current Radiopharmaceuticals is recognized for its impactful contributions, holding a record of Q3 in Pharmacology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023, illustrating its vital role in these domains. The journal aims to provide a comprehensive overview of the latest techniques, applications, and innovations within the field of radiopharmaceutical science, catering to a diverse audience of researchers, professionals, and students. Despite its significant contributions, the journal remains committed to enriching the academic community with high-quality, peer-reviewed articles that can be accessed worldwide, reflecting a dedication to open dialogue and knowledge dissemination in radiopharmaceutical research.

The European Journal of Nuclear Medicine and Molecular Imaging is a prestigious, peer-reviewed journal published by Springer, dedicated to advancing the field of nuclear medicine and molecular imaging. With an impressive impact factor and ranked in the Q1 category for both Medicine and Radiology, Nuclear Medicine and Imaging, this journal is a pivotal platform for researchers and practitioners to disseminate significant findings from 1996 to the present, reflecting the evolution of the field. The journal boasts a notable Scopus rank, standing at #8 out of 333 in its category, placing it in the top 3% of published works, which highlights its critical importance in shaping contemporary practices and research innovations. Although it does not offer an open-access model, the journal provides various access options to ensure that important research is accessible to professionals, students, and academics alike. Through rigorous peer review and a commitment to high-quality publication, the European Journal of Nuclear Medicine and Molecular Imaging plays an essential role in the advancement of nuclear medicine, contributing to better diagnostic and therapeutic outcomes globally.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.